Endocrine Pharmacology USMLE Step 1 Practice Question

A 59-year-old woman with type 2 diabetes mellitus and a history of compensated heart failure with reduced ejection fraction (last echocardiogram showing EF of 40%) presents to her primary care physician for a follow-up visit. Two months ago, she was started on a new oral antidiabetic medication that activates a nuclear receptor to increase adiponectin levels and improve peripheral insulin sensitivity. At today's visit, her blood pressure is 138/86 mmHg, heart rate is 92/min, and weight has increased by 4.5 kg since her last appointment. Physical examination reveals 2+ pitting edema of the bilateral lower extremities and bibasilar crackles on lung auscultation. Her hemoglobin A1c has improved from 8.4% to 7.1%, but she reports progressive dyspnea on exertion and orthopnea over the past three weeks. Which of the following drugs is most likely responsible for her worsening symptoms?